selected scholarly activity
-
academic article
- Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. Scientific Reports. 12:13207. 2022
- Sustained Delivery of a Monoclonal Antibody against SARS-CoV-2 by Microencapsulated Cells: A Proof-of-Concept Study. Pharmaceutics. 14:2042-2042. 2022
- High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination. PLoS ONE. 17:e0272008-e0272008. 2022
- Mesenchymal Stem Cells Coated with Synthetic Bone-Targeting Polymers Enhance Osteoporotic Bone Fracture Regeneration. Bioengineering. 7:125-125. 2020
- Transmission of HIV and HCV within Former Soviet Union Countries. Canadian Journal of Gastroenterology and Hepatology. 2020:1-10. 2020
- Mesenchymal stem cells modifications for enhanced bone targeting and bone regeneration. Regenerative Medicine. 15:1579-1594. 2020
- Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations. Frontiers in Immunology. 11:571319. 2020
- Cell Encapsulation Within Alginate Microcapsules: Immunological Challenges and Outlook. Frontiers in Bioengineering and Biotechnology Frontiers in Bioengineering and Biotechnology. 7:380. 2019
- Detection of Hepatitis E Antibodies in Kazakhstan: A Pilot Study. Central Asian Journal of Global Health. 7:324. 2018
- Molecular epidemiology of HIV-1 subtype A in former Soviet Union countries. PLoS ONE. 13:e0191891-e0191891. 2018
- nMET, A New Target in Recurrent Cancer. Current Cancer Drug Targets. 16:572-578. 2016
- Chitosan DNA nanoparticles for oral gene delivery. World Journal of Medical Genetics. 6:22-22. 2016
- Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells. Artificial Cells, Nanomedicine and Biotechnology. 43:318-327. 2015
- Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells. Journal of Gene Medicine. 16:131-142. 2014
- Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules. Artificial Cells, Nanomedicine and Biotechnology. 42:102-109. 2014
- Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers. Journal of Biological Engineering. 6:7. 2012
- Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model. Gene Therapy. 19:355-364. 2012
- Single-colour flow cytometric assay to determine NK cell-mediated cytotoxicity and viability against non-adherent human tumor cells. Biotechnology Letters Biotechnology Techniques. 34:447-453. 2012
- Encapsulation of factor IX–engineered mesenchymal stem cells in fibrinogen–alginate microcapsules enhances their viability and transgene secretion. Journal of Tissue Engineering. 3:204173141246201-204173141246201. 2012
- Co-Administration Therapy Modulates Immunity to FVIII In Hemophilia A Mice. Blood. 118:1219-1219. 2011
- Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. Journal of Thrombosis and Haemostasis. 8:2743-2750. 2010
- Monkey business for hemophilia management. Thrombosis Research. 126:365-366. 2010
-
Characterization of viability and proliferation of alginate‐poly‐
L ‐lysine–alginate encapsulated myoblasts using flow cytometry. Journal of Biomedical Materials Research - Part B Applied Biomaterials Journal of Biomedical Materials Research. 94B:296-304. 2010 - Therapeutic applications of cell microencapsulation. Foreword.. Advances in Experimental Medicine and Biology. 670:vii-viii. 2010
- Early Intraplatelet Signaling Enhances the Release of Human Platelet PAR-1 and -4 Amino-Terminal Peptides in Response to Thrombin. Biochemistry. 48:1562-1572. 2009
- Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thrombosis and Haemostasis. 99:874-882. 2008
- Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. Journal of Gene Medicine. 9:1002-1010. 2007
- Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Journal of Gene Medicine. 8:362-369. 2006
- Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. Journal of Gene Medicine. 7:1482-1491. 2005
- Continuous antigenic stimulation system (CASS) as a new immunization strategy. Vaccine. 22:3902-3910. 2004
- Nonviral Gene Therapy Approaches to Hemophilia. Seminars in Thrombosis and Hemostasis. 30:197-204. 2004
- History, challenges and perspectives of cell microencapsulation. Trends in Biotechnology. 22:87-92. 2004
- Cell encapsulation: Promise and progress. Nature Medicine. 9:104-107. 2003
- Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. Journal of Gene Medicine. 4:215-223. 2002
- Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia. 7:207-214. 2001
- Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. Journal of Gene Medicine. 2:279-288. 2000
- Therapeutic approaches for haemophilia. Expert Opinion on Therapeutic Patents. 10:929-938. 2000
- Gene Therapy for Hemophilia. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 28:1-24. 2000
- Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable Microcapsules. Human Gene Therapy. 10:1281-1288. 1999
- The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends in Biotechnology. 17:78-83. 1999
- Encapsulation of various recombinant mammalian cell types in different alginate microcapsules. Journal of Biomedical Materials Research - Part B Applied Biomaterials Journal of Biomedical Materials Research. 42:587-596. 1998
- Permeability of alginate microcapsules to secretory recombinant gene products. Biotechnology and Bioengineering. 52:472-484. 1996
- Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 87:5095-5103. 1996
- Growth Retardation—An Unexpected Outcome from Growth Hormone Gene Therapy in Normal Mice with Microencapsulated Myoblasts. Human Gene Therapy. 7:61-70. 1996
- Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy. Human Gene Therapy. 6:165-175. 1995
- Delivery of a Secretable Adenosine Deaminase Through Microcapsules–A Novel Approach to Somatic Gene Therapy. Human Gene Therapy. 5:1445-1455. 1994
- Growth of recombinant fibroblasts in alginate microcapsules. Biotechnology and Bioengineering. 43:925-933. 1994
-
chapter
- 10 Transplants for Hemophilia. 187-203. 2007
- Transplants for Hemophilia. 187-203. 2007
- Gene Therapy Using Encapsulated Cells. 229-247. 2005
- Growth Hormone Gene Therapy Using Encapsulated Myoblasts. 343-350. 1999
-
conference paper
- Ex-Vivo Gene Therapy Approach for Continuous Delivery of BDNF and Its Potential Use for Neurological Disorders (P02.013). Neurology. P02.013-P02.013. 2012
- Ex-Vivo Gene Therapy Approach for Continuous Delivery of BDNF and Its Potential Use for Neurological Disorders (IN6-1.008). Neurology. 2012
- Co-Administration Therapy Modulates Immunity to FVIII In Hemophilia A Mice. Blood. 547-548. 2011
- Dynamic Endovascular, Vascular and Parenchymal Changes during Adult Ischemic Stroke: A Pilot Study. Neurology. A207-A208. 2011
- Oral administration of FVIII DNA as a potential treatment for hemophilia A. Transfusion. 10A-10A. 2008
- An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thrombosis and Haemostasis. 1138-1147. 2005
- Either reducing or increasing the molecular volume of recombinant factor IX accelerates its overall clearance in a mouse model of Hemophilia B. Transfusion. 64A-65A. 2004
- Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology. 565-573. 2004
- Downregulation of immune responses induced by oral DNA administration. Molecular Therapy. S15-S15. 2004
- Partial correction of the hemophilic phenotype in mice implanted with encapsulated human primary myoblasts secreting FIX. Molecular Therapy. S64-S64. 2004
- Accelerated clearance of a recombinant human Factor IX protein lacking activation peptide residues 155-177.. Blood. 91B-91B. 2003
- Oral administration of plasmid DNA results in targeted gene expression and sustained disease correction. Molecular Therapy. S457-S458. 2003
- Somatic gene therapy of mucopolysaccharidosis type II by encapsulated recombinant myoblasts. Molecular Therapy. S393-S394. 2003
- Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatrica, International Journal of Paediatrics, Supplement. 100-104. 2002
- Polymer-encapsulated engineered adult mesenchymal stem cells secrete exogenously regulated rhBMP-2, and induce osteogenic and angiogenic tissue formation. Polymers for Advanced Technologies. 863-870. 2002
- Fusion to albumin alters the clearance of factor IX in vivo. Transfusion. 37S-37S. 2001
- Production of a recombinant factor IX-albumin fusion protein. Transfusion. 29S-30S. 2000
- Therapeutic levels of human factor VIII in mice implanted with encapsulated recombinant myoblasts: Potential for gene therapy of hemophilia A. Transfusion. 1S-1S. 2000
- Sustained delivery of therapeutic levels of human factor IX in nude hemophilic mice implanted with encapsulated mouse myoblasts secreting human factor IX. Thrombosis and Haemostasis. 279-279. 1999
- APPLICATION OF IMMUNOISOLATION TO SOMATIC GENE-THERAPY. Journal of Cellular Biochemistry. 7-7. 1995
- ALLOGENEIC SOMATIC GENE-THERAPY - CORRECTION OF GROWTH-HORMONE DEFICIENCY IN DWARF MICE WITH MICRO-ENCAPSULATED NON-AUTOLOGOUS MYOBLASTS. American Journal of Human Genetics. 107-107. 1993
-
thesis